CPRX (CPRX)
Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Market Cap
—
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
—
Beta
—
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
No company overview is available for CPRX yet.
Peers in Biotechnology
All in industry →VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%
Recent press releases
CPRX has not issued a press release in this window.
SEC filings
All filings →CPRX has not filed an SEC document in this window.
Insider trades
All insider trades →CPRX has no reported insider trades in the last 90 days.
Institutional holders
All holders →As of 2025-12-31 · prior 2025-09-30
BlackRock, Inc.$434.7M
18,626,781 sh+2.3%
STATE STREET CORP$161.2M
6,907,622 sh+7.8%
MORGAN STANLEY$68.5M
2,933,399 sh+59.1%
1,719,767 sh+200.6%
VANGUARD GROUP INC$196.8M
8,432,247 sh-3.2%
2,996,297 sh+21.9%
3,025,271 sh+19.7%
778,591 sh● NEW
People at CPRX
All people →Quarterly financials
Full financials →Revenue trend
03/25
$21.0K
NI $56.7M
06/25
$146.6M
NI $52.1M
09/25
$148.4M
NI $52.8M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $0.42
Prior: $0.41
Revenue sparkline